Center-Authored Papers

Filters: Author is Hay, Kevin A  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
G
Gust J, Hay KA, Hanafi L-A, Li D, Myerson D, Gonzalez-Cuyar LF, Yeung C, Liles CW, Wurfel M, Lopez JA et al..  2017.  Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells.. Cancer discovery. 7(12):1404-1419. Abstract
H
Hay KA, Gauthier J, Hirayama AV, Voutsinas JM, Wu Q, Li D, Gooley TA, Cherian S, Chen X, Pender BS et al..  2019.  Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy.. Blood. 133(15):1652-1663. Abstract
Hay KA, Hanafi L-A, Li D, Gust J, Liles CW, Wurfel MM, López JA, Chen J, Chung D, Harju-Baker S et al..  2017.  Kinetics and Biomarkers of Severe Cytokine Release Syndrome after CD19 Chimeric Antigen Receptor-modified T Cell Therapy.. Blood. 130(21):2295-2306. Abstract
Hay KA, Turtle CJ.  2017.  Chimeric Antigen Receptor (CAR) T Cells: Lessons Learned from Targeting of CD19 in B-Cell Malignancies.. Drugs. Abstract
T
Turtle CJ, Hay KA, Hanafi L-A, Li D, Cherian S, Chen X, Wood B, Lozanski A, Byrd JC, Heimfeld S et al..  2017.  Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 35(26):3010-3020. Abstract